Diabetes, Metabolic Syndrome and Obesity

Real World Evidence for the Pharmacological Treatment of Diabetes: From Clinical Trials to Routine Practice

Diabetes mellitus represents one of the most pressing global health challenges of the 21st century, affecting over 500 million adults worldwide. The pharmacological landscape for diabetes has expanded rapidly, with the introduction of incretin-based therapies, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and dual-acting agents alongside established glucose-lowering drug classes. While randomized controlled trials (RCTs) remain the gold standard for evaluating therapeutic efficacy, their strict inclusion criteria, controlled settings, and limited follow-up durations often restrict the generalizability of findings to diverse, real-world patient populations. This Article Collection presents the latest advances in RWE research specifically pertaining to the pharmacological treatment of diabetes, ultimately informing evidence-based prescribing and clinical decision-making.